首页 > 最新文献

Canadian Journal of Respiratory, Critical Care, and Sleep Medicine最新文献

英文 中文
Chapter 15: Monitoring tuberculosis program performance 第15章:监测结核病项目的绩效
IF 0.8 Q3 RESPIRATORY SYSTEM Pub Date : 2022-03-24 DOI: 10.1080/24745332.2022.2035123
C. Heffernan, M. Haworth-Brockman, P. Plourde, T. Wong, G. Ferrara, R. Long
atuberculosis program evaluation and research unit, department of Medicine, faculty of Medicine and dentistry, university of alberta, edmonton, alberta, Canada; bnational Collaborating Centre for infectious diseases, rady faculty of Health sciences, university of Manitoba, Winnipeg, Manitoba, Canada; cMax rady College of Medicine, rady faculty of Health sciences, university of Manitoba; Winnipeg regional Health authority, Winnipeg, Manitoba, Canada; dpublic Health for indigenous services Canada; Centre for Communicable diseases and infection Control, public Health agency of Canada, ottawa, ontario, Canada
加拿大艾伯塔省埃德蒙顿市阿尔伯塔大学医学与牙科学院医学部结核病项目评估与研究单位;加拿大马尼托巴省温尼伯马尼托巴大学卫生科学学院国家传染病合作中心;曼尼托巴大学雷迪医学院、雷迪健康科学学院;加拿大马尼托巴省温尼伯的温尼伯地区卫生局;加拿大土著服务公共卫生;加拿大公共卫生署传染病和感染控制中心,加拿大安大略省渥太华
{"title":"Chapter 15: Monitoring tuberculosis program performance","authors":"C. Heffernan, M. Haworth-Brockman, P. Plourde, T. Wong, G. Ferrara, R. Long","doi":"10.1080/24745332.2022.2035123","DOIUrl":"https://doi.org/10.1080/24745332.2022.2035123","url":null,"abstract":"atuberculosis program evaluation and research unit, department of Medicine, faculty of Medicine and dentistry, university of alberta, edmonton, alberta, Canada; bnational Collaborating Centre for infectious diseases, rady faculty of Health sciences, university of Manitoba, Winnipeg, Manitoba, Canada; cMax rady College of Medicine, rady faculty of Health sciences, university of Manitoba; Winnipeg regional Health authority, Winnipeg, Manitoba, Canada; dpublic Health for indigenous services Canada; Centre for Communicable diseases and infection Control, public Health agency of Canada, ottawa, ontario, Canada","PeriodicalId":9471,"journal":{"name":"Canadian Journal of Respiratory, Critical Care, and Sleep Medicine","volume":"96 1","pages":"229 - 241"},"PeriodicalIF":0.8,"publicationDate":"2022-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77717894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Chapter 9: Pediatric tuberculosis 第九章:儿童结核病
IF 0.8 Q3 RESPIRATORY SYSTEM Pub Date : 2022-03-24 DOI: 10.1080/24745332.2022.2043055
R. Dwilow, C. Hui, F. Kakkar, I. Kitai
apediatric infectious diseases and Medical Microbiology, Max rady College of Medicine, university of Manitoba, Winnipeg, Manitoba, Canada; bfaculty of Medicine, university of ottawa, Children’s Hospital of eastern ontario, ottawa, ontario, Canada; cfaculty of Medicine, department of pediatrics, université de Montréal, Centre Hospitalier universitaire sainte-Justine, Montreal, Québec, Canada; dfaculty of Medicine, department of paediatrics, university of toronto, Hospital for sick Children, toronto, ontario, Canada
加拿大马尼托巴省温尼伯市曼尼托巴大学Max rady医学院儿科传染病和医学微生物学;渥太华大学医学院,加拿大安大略省渥太华东安大略儿童医院;加拿大魁北克省蒙特利尔市圣贾斯汀大学医院中心,蒙特利尔省医学院,儿科学系;加拿大安大略省多伦多市多伦多大学儿童医院儿科医学系
{"title":"Chapter 9: Pediatric tuberculosis","authors":"R. Dwilow, C. Hui, F. Kakkar, I. Kitai","doi":"10.1080/24745332.2022.2043055","DOIUrl":"https://doi.org/10.1080/24745332.2022.2043055","url":null,"abstract":"apediatric infectious diseases and Medical Microbiology, Max rady College of Medicine, university of Manitoba, Winnipeg, Manitoba, Canada; bfaculty of Medicine, university of ottawa, Children’s Hospital of eastern ontario, ottawa, ontario, Canada; cfaculty of Medicine, department of pediatrics, université de Montréal, Centre Hospitalier universitaire sainte-Justine, Montreal, Québec, Canada; dfaculty of Medicine, department of paediatrics, university of toronto, Hospital for sick Children, toronto, ontario, Canada","PeriodicalId":9471,"journal":{"name":"Canadian Journal of Respiratory, Critical Care, and Sleep Medicine","volume":"52 1","pages":"129 - 148"},"PeriodicalIF":0.8,"publicationDate":"2022-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83528781","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Chapter 4: Diagnosis of tuberculosis infection 第四章:结核感染的诊断
IF 0.8 Q3 RESPIRATORY SYSTEM Pub Date : 2022-03-24 DOI: 10.1080/24745332.2022.2036503
J. Campbell, C. Pease, P. Daley, M. Pai, D. Menzies
• The primary goal of testing for tuberculosis infection is to identify individuals who are at increased risk for the development of tuberculosis disease and who therefore would benefit from tuberculosis preventive treatment. • Testing for tuberculosis infection is NOT recommended in the following situations: ○ In persons who have a low risk of infection and if infected; ○ To support a tuberculosis disease diagnosis in adults and adolescents >12 years of age; ○ For routine mass screening of individuals outside of contact investigations or occupational screening programs; and ○ For the monitoring of tuberculosis disease treatment response. • Both the tuberculin skin test and interferon-gamma release assay are acceptable alternatives for tuberculosis infection diagnosis. Either test can be used for tuberculosis infection screening in any of the situations in which testing is indicated. However, there are preferences and exceptions: ○ An interferon-gamma release assay is the preferred test when: ○ children over two years of age and less than 10 years of age previously received a Bacille Calmette-Guérin (BCG) vaccine against tuberculosis; ○ persons at least 10 years of age received a BCG vaccine after infancy (older than one year of age), or received a BCG vaccine more than once and/or are uncertain about when they received a BCG vaccine; ○ adequate training and quality assessment and control are NOT available for tuberculin skin test administration and/or reading, but personnel and facilities to perform interferon-gamma release assays are available; ○ a person is unable or unlikely to return to have their tuberculin skin test read; or ○ tuberculin skin testing is contraindicated. ○ The tuberculin skin test is the preferred test when serial testing is planned to assess risk of new infection (ie, conversions). This includes repeat testing in a contact investigation, or serial testing of health care workers or other populations (eg, corrections staff or prison inmates) with potential for ongoing exposure. In these situations, interferon-gamma release assays are not acceptable. • Both tuberculosis infection diagnostic tests may be used sequentially in the following situations: ○ If either the tuberculin skin test or interferon-gamma release assay are negative, the other test may be used to increase sensitivity if the risk for infection is high, the risk for progression to tuberculosis disease is elevated, the risk for a poor outcome from tuberculosis disease is high and/or a person has conditions or habits that may reduce the sensitivity of the test. ○ If the initial tuberculin skin test is positive, but the likelihood of tuberculosis infection is low, or risk of a false positive result due to BCG is high, then an interferon-gamma release assay may be used to increase specificity. • When interpreting a tuberculosis infection diagnostic test result and considering whether someone is at risk of developing tuberculosis disease and would likely benefit from
•结核病感染检测的主要目标是确定哪些人患结核病的风险增加,从而可以从结核病预防治疗中受益。•在以下情况下,不建议进行结核病感染检测:〇感染风险低的人,如果感染;〇支持对12岁以上的成人和青少年进行结核病诊断;〇对接触者调查或职业筛查项目之外的个人进行常规大规模筛查;〇监测结核病治疗反应。结核菌素皮肤试验和γ干扰素释放试验都是结核感染诊断可接受的替代方法。在任何需要检测的情况下,这两种检测都可用于结核感染筛查。然而,有偏好和例外:干扰素- γ释放试验是首选的测试,当:〇2岁以上和10岁以下的儿童以前接受过卡介苗(卡介苗)结核病;〇至少10岁的人在婴儿期(1岁以上)后接种卡介苗,或多次接种卡介苗和/或不确定何时接种卡介苗;对于结核菌素皮肤试验的管理和/或读数,没有足够的培训和质量评估与控制,但有进行干扰素释放试验的人员和设施;〇无法或不太可能返回进行结核菌素皮肤试验;结核菌素皮肤试验是禁忌。〇当计划进行系列试验以评估新感染(即转化)的风险时,结核菌素皮肤试验是首选试验。这包括在接触者调查中进行重复检测,或对可能持续接触的卫生保健工作者或其他人群(如惩戒人员或监狱囚犯)进行连续检测。在这些情况下,干扰素释放试验是不可接受的。•在下列情况下,可依次使用两种结核病感染诊断试验:〇如果结核菌素皮肤试验或干扰素- γ释放试验结果均为阴性,则如果感染风险高、结核病进展风险升高、结核病预后不良的风险高和/或患者有可能降低试验敏感性的条件或习惯,则可使用另一种试验来增加敏感性。〇如果最初结核菌素皮肤试验呈阳性,但结核感染的可能性较低,或由于卡介苗导致假阳性结果的风险较高,则可使用干扰素释放试验来增加特异性。•在解释结核病感染诊断测试结果并考虑某人是否有患结核病的风险并可能受益于结核病预防性治疗时,应根据其他因素考虑诊断测试结果,包括该人真正感染的预测试概率、个人患结核病的风险以及测试确定有患结核病风险的人的能力(即:预测价值)。现有的在线工具支持这种解释。
{"title":"Chapter 4: Diagnosis of tuberculosis infection","authors":"J. Campbell, C. Pease, P. Daley, M. Pai, D. Menzies","doi":"10.1080/24745332.2022.2036503","DOIUrl":"https://doi.org/10.1080/24745332.2022.2036503","url":null,"abstract":"• The primary goal of testing for tuberculosis infection is to identify individuals who are at increased risk for the development of tuberculosis disease and who therefore would benefit from tuberculosis preventive treatment. • Testing for tuberculosis infection is NOT recommended in the following situations: ○ In persons who have a low risk of infection and if infected; ○ To support a tuberculosis disease diagnosis in adults and adolescents >12 years of age; ○ For routine mass screening of individuals outside of contact investigations or occupational screening programs; and ○ For the monitoring of tuberculosis disease treatment response. • Both the tuberculin skin test and interferon-gamma release assay are acceptable alternatives for tuberculosis infection diagnosis. Either test can be used for tuberculosis infection screening in any of the situations in which testing is indicated. However, there are preferences and exceptions: ○ An interferon-gamma release assay is the preferred test when: ○ children over two years of age and less than 10 years of age previously received a Bacille Calmette-Guérin (BCG) vaccine against tuberculosis; ○ persons at least 10 years of age received a BCG vaccine after infancy (older than one year of age), or received a BCG vaccine more than once and/or are uncertain about when they received a BCG vaccine; ○ adequate training and quality assessment and control are NOT available for tuberculin skin test administration and/or reading, but personnel and facilities to perform interferon-gamma release assays are available; ○ a person is unable or unlikely to return to have their tuberculin skin test read; or ○ tuberculin skin testing is contraindicated. ○ The tuberculin skin test is the preferred test when serial testing is planned to assess risk of new infection (ie, conversions). This includes repeat testing in a contact investigation, or serial testing of health care workers or other populations (eg, corrections staff or prison inmates) with potential for ongoing exposure. In these situations, interferon-gamma release assays are not acceptable. • Both tuberculosis infection diagnostic tests may be used sequentially in the following situations: ○ If either the tuberculin skin test or interferon-gamma release assay are negative, the other test may be used to increase sensitivity if the risk for infection is high, the risk for progression to tuberculosis disease is elevated, the risk for a poor outcome from tuberculosis disease is high and/or a person has conditions or habits that may reduce the sensitivity of the test. ○ If the initial tuberculin skin test is positive, but the likelihood of tuberculosis infection is low, or risk of a false positive result due to BCG is high, then an interferon-gamma release assay may be used to increase specificity. • When interpreting a tuberculosis infection diagnostic test result and considering whether someone is at risk of developing tuberculosis disease and would likely benefit from","PeriodicalId":9471,"journal":{"name":"Canadian Journal of Respiratory, Critical Care, and Sleep Medicine","volume":"21 1","pages":"49 - 65"},"PeriodicalIF":0.8,"publicationDate":"2022-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90935766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 8
Chapter 2: Transmission and pathogenesis of tuberculosis 第二章:结核病的传播和发病机制
IF 0.8 Q3 RESPIRATORY SYSTEM Pub Date : 2022-03-24 DOI: 10.1080/24745332.2022.2035540
R. Long, M. Divangahi, K. Schwartzman
atuberculosis program evaluation and research unit, department of Medicine, faculty of Medicine and dentistry, university of alberta, edmonton, alberta, Canada; bMeakins-Christie laboratories, research institute of the McGill university Health Centre, Montréal, Québec, Canada; cMcGill international tuberculosis Centre, Montréal, Québec, Canada; ddepartment of Medicine, McGill university, Montréal, Québec, Canada
加拿大艾伯塔省埃德蒙顿市阿尔伯塔大学医学与牙科学院医学部结核病项目评估与研究单位;加拿大麦吉尔大学卫生中心研究所meakins - christie实验室;加拿大麦吉尔国际结核病中心,蒙特里萨,魁特里萨;麦吉尔大学医学系,加拿大麦吉尔
{"title":"Chapter 2: Transmission and pathogenesis of tuberculosis","authors":"R. Long, M. Divangahi, K. Schwartzman","doi":"10.1080/24745332.2022.2035540","DOIUrl":"https://doi.org/10.1080/24745332.2022.2035540","url":null,"abstract":"atuberculosis program evaluation and research unit, department of Medicine, faculty of Medicine and dentistry, university of alberta, edmonton, alberta, Canada; bMeakins-Christie laboratories, research institute of the McGill university Health Centre, Montréal, Québec, Canada; cMcGill international tuberculosis Centre, Montréal, Québec, Canada; ddepartment of Medicine, McGill university, Montréal, Québec, Canada","PeriodicalId":9471,"journal":{"name":"Canadian Journal of Respiratory, Critical Care, and Sleep Medicine","volume":"3 1","pages":"22 - 32"},"PeriodicalIF":0.8,"publicationDate":"2022-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74341464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 12
CTS Focus on Equity, Diversity and Inclusion CTS注重公平、多元和包容
IF 0.8 Q3 RESPIRATORY SYSTEM Pub Date : 2022-03-04 DOI: 10.1080/24745332.2022.2044669
Paul Hernandez
{"title":"CTS Focus on Equity, Diversity and Inclusion","authors":"Paul Hernandez","doi":"10.1080/24745332.2022.2044669","DOIUrl":"https://doi.org/10.1080/24745332.2022.2044669","url":null,"abstract":"","PeriodicalId":9471,"journal":{"name":"Canadian Journal of Respiratory, Critical Care, and Sleep Medicine","volume":"61 1","pages":"71 - 72"},"PeriodicalIF":0.8,"publicationDate":"2022-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85298024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Giant necrotizing cavities in a young individual with septic shock 感染性休克的年轻人出现巨大坏死性空洞
IF 0.8 Q3 RESPIRATORY SYSTEM Pub Date : 2022-02-23 DOI: 10.1080/24745332.2022.2026842
Jean-Christophe Larose, B. Grondin-Beaudoin, K. Serri
Abstract A 30-year-old Moroccan man presented to our institution with general deterioration and respiratory symptoms evolving over several months. Shortly after admission, he developed progressive respiratory failure, septic shock and cardiomyopathy. A diagnosis of severe Mycobacterium tuberculosis infection was made. Despite appropriate antimicrobial therapy, aggressive respiratory and hemodynamic support, the patient had a fulminant course and died of refractory shock. Chest computed tomography scan showed extensive parenchymal destruction and multiple necrotizing cavities. Here, we review the causes leading to giant necrotizing pulmonary cavities and discuss mycobacterium-related septic shock.
摘要一名30岁的摩洛哥男子在几个月的时间里出现一般性恶化和呼吸道症状。入院后不久,他出现了进行性呼吸衰竭、感染性休克和心肌病。诊断为严重结核分枝杆菌感染。尽管给予适当的抗菌药物治疗,积极的呼吸和血流动力学支持,患者仍出现暴发性病程并死于难治性休克。胸部计算机断层扫描显示广泛的实质破坏和多个坏死性空洞。在此,我们回顾导致巨大坏死性肺腔的原因,并讨论与分枝杆菌相关的脓毒性休克。
{"title":"Giant necrotizing cavities in a young individual with septic shock","authors":"Jean-Christophe Larose, B. Grondin-Beaudoin, K. Serri","doi":"10.1080/24745332.2022.2026842","DOIUrl":"https://doi.org/10.1080/24745332.2022.2026842","url":null,"abstract":"Abstract A 30-year-old Moroccan man presented to our institution with general deterioration and respiratory symptoms evolving over several months. Shortly after admission, he developed progressive respiratory failure, septic shock and cardiomyopathy. A diagnosis of severe Mycobacterium tuberculosis infection was made. Despite appropriate antimicrobial therapy, aggressive respiratory and hemodynamic support, the patient had a fulminant course and died of refractory shock. Chest computed tomography scan showed extensive parenchymal destruction and multiple necrotizing cavities. Here, we review the causes leading to giant necrotizing pulmonary cavities and discuss mycobacterium-related septic shock.","PeriodicalId":9471,"journal":{"name":"Canadian Journal of Respiratory, Critical Care, and Sleep Medicine","volume":"4 1","pages":"209 - 210"},"PeriodicalIF":0.8,"publicationDate":"2022-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90635402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Evaluation of medical emergency team activations in patients with limitations-of-medical-therapy: A retrospective cohort study 评估医疗急救小组对药物治疗受限患者的激活:一项回顾性队列研究
IF 0.8 Q3 RESPIRATORY SYSTEM Pub Date : 2022-02-15 DOI: 10.1080/24745332.2021.2022549
R. Zibdawi, L. Carroll, R. Gibney, D. Mckinlay, Satbir Kullar, S. Bagshaw
Abstract Rationale: Utilization of the medical emergency team (MET) and associated outcomes in patients with limitations-of-medical-therapy (LOMT) are not well understood. Objectives: We aimed to describe and compare characteristics and outcomes following MET activation in patients with and without LOMT. Methods, Measurements and Main Results: Retrospective cohort study of 2,118 adult in-patients with a MET activation between January 1, 2013, to December 31, 2015, at the University of Alberta Hospital in Edmonton, Canada. There were 2,703 MET activations in 2,118 patients. Four hundred sixty-one patients (21%) had LOMT at the time of MET activation. Of these, 268 (58%) died in-hospital, 40% within 24 hours of their last MET activation. Compared to patients with no LOMT, patients with LOMT were older (78 vs. 63 years; p < 0.001), more likely to be female (48% vs. 42%; p < 0.01), had a higher comorbidity index score (6 vs. 5; p < 0.001) and more often admitted to a medical service (66% vs. 45%; p < 0.001). A LOMT was associated with 3.49 greater odds (95% CI: 2.79- 4.36) of in-hospital mortality following MET activation. Conclusions: MET activations in hospitalized patients with preexisting LOMT are common. The findings suggest greater need for understanding the role of MET services for patients with LOMT, particularly nearing end-of-life. Supplemental data for this article is available online at https://doi.org/10.1080/24745332.2021.2022549
基本原理:目前尚不清楚医疗急救小组(MET)的使用情况和药物治疗受限(LOMT)患者的相关结局。目的:我们旨在描述和比较LOMT患者和非LOMT患者MET激活后的特征和结果。方法、测量方法和主要结果:回顾性队列研究了2013年1月1日至2015年12月31日期间在加拿大埃德蒙顿阿尔伯塔大学医院接受MET激活治疗的2118名成年住院患者。在2118名患者中有2703个MET激活。461例患者(21%)在MET激活时发生LOMT。其中,268例(58%)在医院死亡,40%在最后一次MET激活后24小时内死亡。与没有LOMT的患者相比,LOMT患者年龄较大(78岁vs. 63岁;P < 0.001),更有可能是女性(48% vs. 42%;P < 0.01),合并症指数评分较高(6比5;P < 0.001),并且更经常接受医疗服务(66%对45%;p < 0.001)。LOMT与MET激活后住院死亡率增加3.49的几率(95% CI: 2.79- 4.36)相关。结论:MET在已有LOMT的住院患者中激活是常见的。研究结果表明,更有必要了解MET服务对LOMT患者的作用,特别是接近生命末期的患者。本文的补充数据可在https://doi.org/10.1080/24745332.2021.2022549上在线获得
{"title":"Evaluation of medical emergency team activations in patients with limitations-of-medical-therapy: A retrospective cohort study","authors":"R. Zibdawi, L. Carroll, R. Gibney, D. Mckinlay, Satbir Kullar, S. Bagshaw","doi":"10.1080/24745332.2021.2022549","DOIUrl":"https://doi.org/10.1080/24745332.2021.2022549","url":null,"abstract":"Abstract Rationale: Utilization of the medical emergency team (MET) and associated outcomes in patients with limitations-of-medical-therapy (LOMT) are not well understood. Objectives: We aimed to describe and compare characteristics and outcomes following MET activation in patients with and without LOMT. Methods, Measurements and Main Results: Retrospective cohort study of 2,118 adult in-patients with a MET activation between January 1, 2013, to December 31, 2015, at the University of Alberta Hospital in Edmonton, Canada. There were 2,703 MET activations in 2,118 patients. Four hundred sixty-one patients (21%) had LOMT at the time of MET activation. Of these, 268 (58%) died in-hospital, 40% within 24 hours of their last MET activation. Compared to patients with no LOMT, patients with LOMT were older (78 vs. 63 years; p < 0.001), more likely to be female (48% vs. 42%; p < 0.01), had a higher comorbidity index score (6 vs. 5; p < 0.001) and more often admitted to a medical service (66% vs. 45%; p < 0.001). A LOMT was associated with 3.49 greater odds (95% CI: 2.79- 4.36) of in-hospital mortality following MET activation. Conclusions: MET activations in hospitalized patients with preexisting LOMT are common. The findings suggest greater need for understanding the role of MET services for patients with LOMT, particularly nearing end-of-life. Supplemental data for this article is available online at https://doi.org/10.1080/24745332.2021.2022549","PeriodicalId":9471,"journal":{"name":"Canadian Journal of Respiratory, Critical Care, and Sleep Medicine","volume":"71 1","pages":"291 - 297"},"PeriodicalIF":0.8,"publicationDate":"2022-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87842427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Resumption of pulmonary function testing during the COVID-19 pandemic COVID-19大流行期间恢复肺功能检测
IF 0.8 Q3 RESPIRATORY SYSTEM Pub Date : 2022-01-27 DOI: 10.1080/24745332.2021.2010478
S. Stanojevic, François Beaucage, Vikram R. Comondore, M. Faughnan, T. Kovesi, C. McCoy, C. Mcparland, D. Pawluski, F. Refahi, Jeremy Road, M. Kooperberg
As we progress toward an endemic phase of the COVID-19 pandemic, there is a need to re-evaluate which pandemic precautions should be maintained for performance of pulmonary function tests (PFT). Specifically, how should risk be mitigated for patients and health care workers as the dynamics of viral transmission evolve over time. This third update of the Resumption of PFTs in the era of COVID-19 presents the current evidence to support performance of PFT in dedicated laboratories and in primary care settings across Canada. Throughout the
随着COVID-19大流行进入流行阶段,有必要重新评估在肺功能测试(PFT)中应保持哪些大流行预防措施。具体来说,随着病毒传播的动态随着时间的推移而演变,应该如何减轻患者和卫生保健工作者的风险。本报告第三次更新了2019冠状病毒病时期恢复PFT的情况,介绍了目前支持加拿大各地专用实验室和初级保健机构开展PFT的证据。在整个
{"title":"Resumption of pulmonary function testing during the COVID-19 pandemic","authors":"S. Stanojevic, François Beaucage, Vikram R. Comondore, M. Faughnan, T. Kovesi, C. McCoy, C. Mcparland, D. Pawluski, F. Refahi, Jeremy Road, M. Kooperberg","doi":"10.1080/24745332.2021.2010478","DOIUrl":"https://doi.org/10.1080/24745332.2021.2010478","url":null,"abstract":"As we progress toward an endemic phase of the COVID-19 pandemic, there is a need to re-evaluate which pandemic precautions should be maintained for performance of pulmonary function tests (PFT). Specifically, how should risk be mitigated for patients and health care workers as the dynamics of viral transmission evolve over time. This third update of the Resumption of PFTs in the era of COVID-19 presents the current evidence to support performance of PFT in dedicated laboratories and in primary care settings across Canada. Throughout the","PeriodicalId":9471,"journal":{"name":"Canadian Journal of Respiratory, Critical Care, and Sleep Medicine","volume":"32 1","pages":"78 - 81"},"PeriodicalIF":0.8,"publicationDate":"2022-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82918738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
In memoriam of Dr. Mark FitzGerald, MD, MB, FCCP, FRCPI, FRCPC 纪念Mark FitzGerald博士,MD, MB, FCCP, FRCPI, FRCPC
IF 0.8 Q3 RESPIRATORY SYSTEM Pub Date : 2022-01-02 DOI: 10.1080/24745332.2022.2035854
L. Boulet, M. Sadatsafavi, P. O'Byrne
{"title":"In memoriam of Dr. Mark FitzGerald, MD, MB, FCCP, FRCPI, FRCPC","authors":"L. Boulet, M. Sadatsafavi, P. O'Byrne","doi":"10.1080/24745332.2022.2035854","DOIUrl":"https://doi.org/10.1080/24745332.2022.2035854","url":null,"abstract":"","PeriodicalId":9471,"journal":{"name":"Canadian Journal of Respiratory, Critical Care, and Sleep Medicine","volume":"42 1","pages":"4 - 5"},"PeriodicalIF":0.8,"publicationDate":"2022-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84688281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
President’s recommended reading list: Bibliotherapy during a pandemic 总统推荐阅读书单:传染病期间的阅读疗法
IF 0.8 Q3 RESPIRATORY SYSTEM Pub Date : 2022-01-02 DOI: 10.1080/24745332.2022.2027694
Paul O. Hernandez
{"title":"President’s recommended reading list: Bibliotherapy during a pandemic","authors":"Paul O. Hernandez","doi":"10.1080/24745332.2022.2027694","DOIUrl":"https://doi.org/10.1080/24745332.2022.2027694","url":null,"abstract":"","PeriodicalId":9471,"journal":{"name":"Canadian Journal of Respiratory, Critical Care, and Sleep Medicine","volume":"30 1","pages":"1 - 3"},"PeriodicalIF":0.8,"publicationDate":"2022-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89766647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Canadian Journal of Respiratory, Critical Care, and Sleep Medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1